Horizon Pharma (HZNP) KOL Call Highlights A Transformational Opportunity - Piper

Piper Jaffray analyst David Amsellem reiterated an Overweight rating and $33.00 price target on Horizon Pharma (NASDAQ: HZNP) after hosting a KOL call with a professional focusing on moderate-to-severely active thyroid eye disease (TED).

The analyst stated "The commentary clearly underscores the extent to which systemic corticosteroids are inadequate for these patients (i.e., most patients in her practice actually opt against corticosteroid treatment). Though our featured KOL voiced some unanswered questions regarding the body of data surrounding teprotumumab (bearing in mind that detailed Phase III results will be presented later this year), she was nonetheless very clear that she expects to use the product broadly (i.e., in moderate and severe TED patients), particularly given that no other pharmacologic can reduce proptosis (i.e., bulging of the eyes). We continue to view teprotumumab as a potentially transformational opportunity for HZNP."

For an analyst ratings summary and ratings history on Horizon Pharma click here. For more ratings news on Horizon Pharma click here.

Shares of Horizon Pharma closed at $27.34 yesterday.

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• UBS Reiterates Buy Rating on NVIDIA (NVDA), Expects Q2 Revenue Beat
• UBS Reiterates Buy Rating on Hilton Worldwide (HLT)